314.40

1.92% 5.92

After Hours: 314.40

Alnylam Pharmaceuticals Inc (ALNY)

Overview News Price History Option Chain Financials Why ALNY Down? Discussions Forecast

Alnylam Pharmaceuticals Inc stock is traded at $314.40, with a volume of 1.39M. It is up +1.92% in the last 24 hours and down -15.02% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Previous Close:

$308.48

Open:

$302.55

24h Volume:

1.39M

Relative Volume:

0.94

Market Cap:

$41.54B

Revenue:

$3.71B

Net Income/Loss:

$313.75M

P/E Ratio:

139.29

EPS:

2.2571

Net Cash Flow:

$465.38M

1W Performance:

-4.19%

1M Performance:

-15.02%

6M Performance:

-27.31%

1Y Performance:

+18.69%

1-Day Range:

$302.55

$318.44

1-Week Range:

$298.00

$329.92

52-Week Range:

$205.87

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name

Alnylam Pharmaceuticals Inc

Sector

Healthcare (1109)

Industry

Biotechnology (622)

Phone

(617) 551-8200

Address

675 WEST KENDALL STREET, CAMBRIDGE, MA

Employee

2,230

Twitter

@alnylam

Next Earnings Date

2026-02-12

Latest SEC Filings

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.71B	313.75M	465.38M	2.2571
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Jan-07-26	Resumed	Oppenheimer	Outperform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Mar-31-25	Initiated	Redburn Atlantic	Buy
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy
Feb-16-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-26-23	Initiated	SMBC Nikko	Neutral
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Buy
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-01-22	Initiated	Citigroup	Buy
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Nov-22-21	Upgrade	Goldman	Neutral → Buy
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-04-21	Upgrade	UBS	Neutral → Buy
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral
Feb-12-21	Downgrade	Citigroup	Buy → Neutral
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-30-20	Resumed	Berenberg	Hold
Sep-08-20	Initiated	Citigroup	Buy
Aug-11-20	Downgrade	Oppenheimer	Outperform → Perform
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
May-07-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-24-20	Resumed	Evercore ISI	Outperform
Mar-19-20	Initiated	Berenberg	Buy
Dec-19-19	Reiterated	Chardan Capital Markets	Buy
Nov-20-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
May-23-19	Resumed	Goldman	Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-06-19	Upgrade	Evercore ISI	In-line → Outperform
Mar-05-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-23-19	Initiated	UBS	Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-13-18	Reiterated	Stifel	Buy
Aug-07-18	Upgrade	Stifel	Hold → Buy
May-04-18	Reiterated	Stifel	Hold
Mar-28-18	Initiated	Evercore ISI	In-line

View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

03:07 AM

ABN Amro Investment Solutions Has $597,000 Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

03:07 AM

Feb 16, 2026

Shell Asset Management Co. Sells 4,478 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 16, 2026

Aberdeen Group plc Sells 61,228 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 16, 2026

Feb 15, 2026

Will First GAAP Profit Year and Amvuttra Expansion Shift Alnylam Pharmaceuticals' (ALNY) Narrative? - simplywall.st

Feb 15, 2026

Cardiovascular Biologics Market to Reach US$ 4.23 Billion - openPR.com

Feb 15, 2026

12,116 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Cibc World Market Inc. - MarketBeat

Feb 15, 2026

Feb 14, 2026

Alnylam Pharmaceuticals (ALNY) Turns Profitable With Q4 EPS Of US$1.41 Challenging Bearish Narratives - simplywall.st

Feb 14, 2026

What are analysts’ price targets for Alnylam Pharmaceuticals Inc.Quarterly Performance Summary & Free Expert Verified Stock Movement Alerts - mfd.ru

Feb 14, 2026

Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com

Feb 14, 2026

Is Alnylam Pharmaceuticals (ALNY) one of the best upside stocks to invest in right now? - MSN

Feb 14, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat

Feb 14, 2026

Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? - Insider Monkey

Feb 14, 2026

Feb 13, 2026

Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback? - simplywall.st

Feb 13, 2026

Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations (ALNY) - Seeking Alpha

Feb 13, 2026

RBC Capital lowers Alnylam Pharmaceuticals stock price target on short-term headwinds - Investing.com Canada

Feb 13, 2026

ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down - Bitget

Feb 13, 2026

Demystifying Alnylam Pharmaceuticals: Insights From 13 Analyst Reviews - Benzinga

Feb 13, 2026

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026

RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating - marketscreener.com

Feb 13, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $425.00 at Chardan Capital - MarketBeat

Feb 13, 2026

Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback - Yahoo Finance

Feb 13, 2026

Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) ROE Of 19% Impressive? - Yahoo Finance

Feb 13, 2026

Rhumbline Advisers Sells 3,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Feb 13, 2026

Alnylam turns a profit for first time in 24-year history - The Business Journals

Feb 12, 2026

Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q4 2025 Earnings Conference - 富途牛牛

Feb 12, 2026